The European Medicines Agency (EMA) recommends extension of indications for daratumumabAccess, MyelomaOctober 21, 2019
European Commission approves elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory myelomaAccess, MyelomaAugust 28, 2019
Janssen seeks European marketing authorisation for subcutaneous (under the skin) daratumumab (Darzalex®)Access, MyelomaJuly 19, 2019
HARMONY reaches milestone capturing data from 45,000 patients with blood cancersMPE, MyelomaJune 25, 2019
Takeda announces discontinuation of the phase 3 clinical trial TOURMALINE-AL1 in AL amyloidosisAccess, AL amyloidosisJune 6, 2019
ASCO 2019 – Lenalidomide reduces risk that smoldering myeloma will progress to myeloma in high risk patientsConferences, MyelomaMay 31, 2019
